SureTrader
Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Drugs >

Innovation Pharmaceuticals Inc. (IPIX)

IPIX RSS Feed
Add IPIX Price Alert      Hide Sticky   Hide Intro
Moderator: LilKahuna, BooDog, sox040713, Astavakra, Matagordaville, scottsmith
Search This Board: 
Last Post: 12/12/2017 2:50:46 AM - Followers: 732 - Board type: Free - Posts Today: 6

Innovation Pharmaceuticals Inc. (IPIX)

https://www.sec.gov/Archives/edgar/data/1355250/000147793217002710/ctix_8k.htm
 

http://www.ipharminc.com/

 
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
Email:  info@ipharminc.com

 
About Innovation Pharmaceuticals Inc.: 

Headquartered in Beverly, Massachusetts, Innovation Pharmaceuticals is a publicly-traded company under the symbol "IPIX".
Innovation Pharmaceuticals is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Innovation Pharmaceuticals believes it has a world-class portfolio of first-in-class lead drug candidates and is now advancing them toward market approval, while actively seeking strategic partnerships. Innovation Pharmaceuticals' psoriasis drug candidate Prurisol completed a Phase 2 trial and Innovation Pharmaceuticals is nearing completion of a Phase 2b study. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Innovation Pharmaceuticals' anti-cancer drug Kevetrin successfully concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Innovation Pharmaceuticals has commenced a Phase 2 study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Innovation Pharmaceuticals is in a Phase 2 clinical trial with its novel compound Brilacidin-OM (a defensin mimetic compound) for the prevention of oral mucositis in patients with head and neck cancer. Interim analysis has shown Brilacidin-OM to have a high potential for prevention of severe oral mucositis. Clinical results are consistent with those seen in an animal model in which the occurrence of severe ulcerative oral mucositis was reduced by more than 94% compared to placebo. Innovation Pharmaceuticals' lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infection, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria ("superbugs"). In an ongoing Phase 2 open label Proof-of-Concept trial, favorable interim results have been observed in the first two cohorts of patients treated with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD).  Innovation Pharmaceuticals has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available at http://www.ipharminc.com.

Management: http://www.cellceutix.com/senior-management/

Ongoing Human Trials:  http://clinicaltrials.gov/ct2/results?term=Cellceutix+Pharmaceuticals&Search=Search
 
Product Pipeline:  http://www.ipharminc.com/therapeutic-areas/

 

PIPELINE: 

FDA DESIGNATIONS:

MILESTONES:


Recent News and Press Releases: 
https://finance.yahoo.com/quote/IPIX?p=IPIX
http://www.ipharminc.com/press-release/

 
SEC Filings (CIK:0001355250): 
https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com

 
Share Structure:  See SEC filing link above for current share structure

 

Cellceutix IP - Patent Filings:

EPO
http://worldwide.espacenet.com/searchResults?PA=Cellceutix&DB=EPODOC&locale=en_EP&ST=advanced&compact=false
WIPO
http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2010135170&recNum=1&docAn=US2010034838&queryString=FP:(Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Cellceutix&FIELD1=AS&co1=AND&TERM2=&FIELD2=&d=PG01 


http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,796,275.PN.&OS=PN/8,796,275&RS=PN/8,796,275
 

Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
 
External Links: USPTO, USPTO Assignment, Espacenet

http://www.google.com/patents/US8338454

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=6&f=G&l=50&co1=AND&d=PG01&s1=Cellceutix.AS.&OS=AN/Cellceutix&RS=AN/Cellceutix

 
Investor Relations: 

http://www.ipharminc.com/new-faq/
http://www.ipharminc.com/contact-us-1


Following is a DAILY chart:


 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

SureTrader
Interactive Brokers Advertisement
IPIX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IPIX News: Prospectus Filed Pursuant to Rule 424(b)(2) (424b2) 11/13/2017 10:03:05 AM
IPIX News: Quarterly Report (10-q) 11/08/2017 04:04:57 PM
IPIX News: Notice of Effectiveness (effect) 09/22/2017 06:02:17 AM
IPIX News: Securities Registration Statement (simplified Form) (s-3) 09/11/2017 12:47:10 PM
IPIX News: Annual Report (10-k) 09/11/2017 06:04:38 AM
PostSubject
#207221  Sticky Note Re B-OM Ph2 topline: A Lead-Off Stand-Up Double slcimmuno 12/11/17 08:36:46 AM
#205289  Sticky Note Due diligence: Innovation Pharmaceuticals Inc. (IPIX) BooDog 11/30/17 06:20:08 AM
#200267  Sticky Note Cellceutix Reports Very Encouraging Interim Analysis of Phase scottsmith 10/16/17 07:19:09 PM
#200091  Sticky Note IPIX Clinical Trial Timelines sox040713 10/14/17 08:13:18 PM
#197995  Sticky Note IPIX Milestones, Clinical Trials, Recent Interviews, Corporate Overview, Patents sox040713 09/24/17 05:24:48 PM
#187085  Sticky Note When it is easier to find an off IH Admin [Edward] 06/23/17 04:39:38 PM
#199298   FINRA Short Interest of IPIX sox040713 10/06/17 11:00:19 PM
#199296   If the call option is .70, you still LilKahuna 10/06/17 10:36:22 PM
#199294   If you buy a share you buy the scottsmith 10/06/17 10:07:05 PM
#199293   not on any board that ive seen untohim 10/06/17 09:57:30 PM
#199292   Well stated. I was reacting to the more LilKahuna 10/06/17 09:55:38 PM
#199291   You have no obligation to buy anything further frrol 10/06/17 09:54:47 PM
#199290   Opinions go better with some reason and rationality. frrol 10/06/17 09:51:09 PM
#199288   Yes buy the buyer isn't obligated to actually scottsmith 10/06/17 09:16:15 PM
#199287   Well this so called risky option is why untohim 10/06/17 09:10:01 PM
#199286   Their point is that at such a "low" frrol 10/06/17 09:03:51 PM
#199285   FINRA short sales of IPIX AlanC 10/06/17 09:01:51 PM
#199284   Options are a wasting asset often worthless on bradfordbros 10/06/17 08:43:36 PM
#199283   As risky as an option. Options are a LilKahuna 10/06/17 08:24:36 PM
#199282   More risky than an option. scottsmith 10/06/17 07:31:18 PM
#199281   Yes a perpetual option groton68 10/06/17 07:29:57 PM
#199280   Options... a good word since the share price KarinCA 10/06/17 07:25:10 PM
#199279   Options. And we shouldn’t have to wait long groton68 10/06/17 07:21:00 PM
#199278   OM will soon to be a billion dollar sox040713 10/06/17 07:20:56 PM
#199277   Yes, B-OM can fall into oncology, but, it KarinCA 10/06/17 07:08:00 PM
#199276   groton68,one BP partner for the entire Brilacidin platform biodoc 10/06/17 06:48:32 PM
#199275   I'm surprised to hear a "long and strong" sox040713 10/06/17 06:34:06 PM
#199274   OM will be YUUGGGEEEEE. Can't wait for those septmike09 10/06/17 06:23:45 PM
#199273   Agreed... and, that's why I bought a bit KarinCA 10/06/17 06:14:39 PM
#199272   That was already explained many times. Just look septmike09 10/06/17 06:02:47 PM
#199271   P is more promising than ever. Shareholders will septmike09 10/06/17 05:50:01 PM
#199270   Echo agree, so why hasn't he released the JTORENCE 10/06/17 05:28:20 PM
#199269   JTORRENCE The test results power over other information. Echo20 10/06/17 05:11:44 PM
#199268   Wasn't P always the wild card? I don't DesireToLearn 10/06/17 05:11:07 PM
#199267   P was so promising to cancel interim and Rdunn88 10/06/17 04:48:02 PM
#199266  Restored ...will see shorty... georgejjl 10/06/17 04:35:03 PM
#199265   George yada yada yada, not giving interim up JTORENCE 10/06/17 04:21:03 PM
#199264   Maxdud Junk is turned into gold on this stock. Echo20 Echo20 10/06/17 04:13:00 PM
#199263   .60s next week as Leo runs to the Rdunn88 10/06/17 04:11:19 PM
#199262   Georgejji Which pharma will go first? Echo20 Echo20 10/06/17 04:10:51 PM
#199261   Think about this: The current Prurisol trial will georgejjl 10/06/17 04:01:02 PM
#199260   When will this stock start to move? This snayeman 10/06/17 03:28:18 PM
#199259   Love your idea. Only problem is flush with groton68 10/06/17 03:22:59 PM
#199258   Thanks. TheDane 10/06/17 02:30:57 PM
#199257   I am hoping for a merger acquisition of tryz 10/06/17 02:22:15 PM
#199256   Some hints: romaa 10/06/17 02:22:12 PM
#199255   PUT YOUR STOCK UP FOR SALE, IF YOU annakneemuss 10/06/17 02:05:30 PM
#199254   I agree. Trial results will be a surprise. scottsmith 10/06/17 01:51:18 PM
#199253   I posed a question to Art some time groton68 10/06/17 01:48:02 PM
#199252   What makes you believe that? TheDane 10/06/17 01:39:25 PM
#199251   I believe a big surprise is in the romaa 10/06/17 01:32:14 PM
#199250   Posting history is a tell. OM is a Williamsc 10/06/17 01:12:36 PM
#199249   I think you're right about results. I suspect frrol 10/06/17 01:10:48 PM
#199248   Brilacidin for Oral Mucositis is unlikely to be KarinCA 10/06/17 12:53:17 PM
#199247   The reality is, most people aren't obsessed with DaysOnTheBeach 10/06/17 10:54:32 AM
#199246   I think he and team know what they DaubersUP 10/06/17 10:30:47 AM
PostSubject